Literature DB >> 18721717

Effect of nepafenac sodium 0.1% on delayed corneal epithelial healing and haze after photorefractive keratectomy: retrospective comparative study.

Shahrokh Jalali1, Leonard H Yuen, Brian S Boxer Wachler.   

Abstract

PURPOSE: To assess delayed epithelialization and corneal haze related to nepafenac ophthalmic suspension 0.1% (Nevanac) use after photorefractive keratectomy (PRK).
SETTING: Private practice, Beverly Hills, California, USA.
METHODS: This retrospective comparative chart review comprised 69 eyes (44 patients) that were divided into 2 treatment groups that were not statistically significantly different in age or preoperative spherical equivalent. The nepafenac group consisted of 34 eyes (22 patients) that received nepafenac 0.1%, moxifloxacin, and fluorometholone postoperatively. The non-nepafenac group included 35 eyes (22 patients) that received moxifloxacin and fluorometholone only. Patients were seen between 1 day and 5 days postoperatively for evaluation of epithelial healing and haze formation. Delayed epithelialization was defined as healing after day 5. All patients were followed for haze formation for a minimum of 3 months.
RESULTS: Statistical analysis showed no difference between the nepafenac and non-nepafenac groups in delayed epithelialization (P = .61, chi-square test). Neither group had significant corneal haze.
CONCLUSION: Nepafenac did not appear to delay corneal epithelial healing or contribute to haze formation after PRK.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18721717     DOI: 10.1016/j.jcrs.2008.04.036

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  2 in total

Review 1.  Corneal Regeneration After Photorefractive Keratectomy: A Review.

Authors:  Javier Tomás-Juan; Ane Murueta-Goyena Larrañaga; Ludger Hanneken
Journal:  J Optom       Date:  2014-10-23

2.  Delayed Epithelial Healing with Corneal Edema and Haze After Photorefractive Keratectomy Using Intraoperative Mitomycin C.

Authors:  Majid Moshirfar; William B West; Dallin C Milner; Shannon E McCabe; Yasmyne C Ronquillo; Phillip C Hoopes
Journal:  Int Med Case Rep J       Date:  2021-12-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.